CCL2 promotes proliferation, migration and angiogenesis through the MAPK/ERK1/2/MMP9, PI3K/AKT, Wnt/β‑catenin signaling pathways in HUVECs

Peng,Zhonghua; Pang,He; Wu,Hang; Peng,Xin; Tan,Qichao; Lin,Sien; Wei,Bo

doi:10.3892/etm.2022.11776

CCL2 promotes proliferation, migration and angiogenesis through the MAPK/ERK1/2/MMP9, PI3K/AKT, Wnt/β‑catenin signaling pathways in HUVECs

Authors:
- Zhonghua Peng
- He Pang
- Hang Wu
- Xin Peng
- Qichao Tan
- Sien Lin
- Bo Wei
View Affiliations

Affiliations: Orthopedics Center, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong 524001, P.R. China
Published online on: December 27, 2022 https://doi.org/10.3892/etm.2022.11776
Article Number: 77
Copyright: © Peng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Severe bone trauma can lead to poor or delayed bone healing and nonunion. Bone regeneration is based on the interaction between osteogenesis and angiogenesis. Angiogenesis serves a unique role in the repair and remodeling of bone defects. Monocyte chemoattractant protein‑1, also known as CC motif ligand 2 (CCL2), is a member of the CC motif chemokine family and was the first human chemokine to be revealed to be an effective chemokine of monocytes. However, its underlying mechanism in angiogenesis of bone defect repair remains to be elucidated. Therefore, the present study investigated the detailed mechanism by which CCL2 promoted angiogenesis in bone defects based on cell and animal model experiments. In the present study, CCL2 promoted proliferation, migration and tube formation in human umbilical vein endothelial cells (HUVECs) in a concentration‑dependent manner. Western blot analysis revealed that treatment of HUVECs with CCL2 upregulated the protein expression levels of rho‑associated coiled‑coil‑containing protein kinase (Rock)1, Rock2, N‑cadherin, c‑Myc and VEGFR2. Furthermore, CCL2 promoted the expression of MAPK/ERK1/2/MMP9, PI3K/AKT and Wnt/β‑catenin signaling pathway‑related proteins, which also demonstrated that CCL2 promoted these functions in HUVECs. Immunohistochemical staining of Sprague Dawley rat femurs following bone defects revealed that VEGF expression was positive in the newly formed bone area in each group, while the expression area of VEGF in the CCL2 addition group was markedly increased. Therefore, CCL2 is a potential therapeutic approach for bone defect repair and reconstruction through the mechanism of angiogenesis‑osteogenesis coupling.

View Figures

View References

1	Freeman F, Burdis R and Kelly DJ: Printing new bones: From print-and-implant devices to bioprinted bone organ precursors. Trends Mol Med. 27:700–711. 2021.PubMed/NCBI View Article : Google Scholar
2	Arealis G and Nikolaou VJ: Bone printing: New frontiers in the treatment of bone defects. Injury 46 Suppl. 8:S20–S22. 2015.PubMed/NCBI View Article : Google Scholar
3	Tateishi-Yuyama E, Matsubara H, Murohara T, Ikeda U, Shintani S, Masaki H, Amano K, Kishimoto Y, Yoshimoto K, Akashi H, et al: Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: A pilot study and a randomised controlled trial. Lancet. 360:427–435. 2002.PubMed/NCBI View Article : Google Scholar
4	McLaughlin KI, Milne TJ, Zafar S, Zanicotti DG, Cullinan MP, Seymour GJ and Coates DE: The in vitro effect of VEGF receptor inhibition on primary alveolar osteoblast nodule formation. Aust Dent J. 65:196–204. 2020.PubMed/NCBI View Article : Google Scholar
5	Moses MA: The regulation of neovascularization of matrix metalloproteinases and their inhibitors. Stem Cells. 15:180–189. 1997.PubMed/NCBI View Article : Google Scholar
6	Holmes K, Roberts OL, Thomas AM and Cross MJ: Vascular endothelial growth factor receptor-2: Structure, function, intracellular signalling and therapeutic inhibition. Cell Signal. 19:2003–2012. 2007.PubMed/NCBI View Article : Google Scholar
7	Risau W: Mechanisms of angiogenesis. Nature. 386:671–674. 1997.PubMed/NCBI View Article : Google Scholar
8	Herzog C, Haun RS, Shah SV and Kaushal GP: Proteolytic processing and inactivation of CCL2/MCP-1 by meprins. Biochem Biophys Rep. 8:146–150. 2016.PubMed/NCBI View Article : Google Scholar
9	Whelan DS, Caplice NM and Clover AJP: Mesenchymal stromal cell derived CCL2 is required for accelerated wound healing. Sci Rep. 10(2642)2020.PubMed/NCBI View Article : Google Scholar
10	Tu MM, Abdel-Hafiz HA, Jones RT, Jean A, Hoff KJ, Duex JE, Chauca-Diaz A, Costello JC, Dancik GM, Tamburini BAJ, et al: Inhibition of the CCL2 receptor, CCR2, enhances tumor response to immune checkpoint therapy. Commun Biol. 3(720)2020.PubMed/NCBI View Article : Google Scholar
11	Anada T, Pan CC, Stahl AM, Mori S, Fukuda J, Suzuki O and Yang Y: Vascularized Bone-mimetic hydrogel constructs by 3D bioprinting to promote osteogenesis and angiogenesis. Int J Mol Sci. 20(1096)2019.PubMed/NCBI View Article : Google Scholar
12	Cao Z, Hao Z, Xin M, Yu L, Wang L, Zhang Y, Zhang X and Guo X: Endogenous and exogenous galectin-3 promote the adhesion of tumor cells with low expression of MUC1 to HUVECs through upregulation of N-cadherin and CD44. Lab Invest. 98:1642–1656. 2018.PubMed/NCBI View Article : Google Scholar
13	Farrell AS and Sears RC: MYC degradation. Cold Spring Harb Perspect Med. 4(a014365)2014.PubMed/NCBI View Article : Google Scholar
14	Hu K and Olsen BR: Osteoblast-derived VEGF regulates osteoblast differentiation and bone formation during bone repair. J Clin Invest. 126:509–526. 2016.PubMed/NCBI View Article : Google Scholar
15	Loirand GJPr: Rho kinases in health and disease: From basic science to translational research. Pharmacol Rev. 67:1074–1095. 2015.PubMed/NCBI View Article : Google Scholar
16	Pai SG, Carneiro BA, Mota JM, Costa R, Leite CA, Barroso-Sousa R, Kaplan JB, Chae YK and Giles FJ: Wnt/beta-catenin pathway: Modulating anticancer immune response. J Hematol Oncol. 10(101)2017.PubMed/NCBI View Article : Google Scholar
17	Pompura SL and Dominguez-Villar M: The PI3K/AKT signaling pathway in regulatory T-cell development, stability, and function. J Leukoc Biol 2018 (Epub ahead of print).
18	Roskoski R Jr: ERK1/2 MAP kinases: Structure, function, and regulation. Pharmacol Res. 66:105–143. 2012.PubMed/NCBI View Article : Google Scholar
19	Lu H, Liu Y, Guo J, Wu H, Wang J and Wu G: Biomaterials with antibacterial and osteoinductive properties to repair infected bone defects. Int J Mol Sci. 17(334)2016.PubMed/NCBI View Article : Google Scholar
20	Stahl A and Yang YP: Regenerative approaches for the treatment of large bone defects. Tissue Eng Part B Rev. 27:539–547. 2021.PubMed/NCBI View Article : Google Scholar
21	Zhu S, Bennett S, Kuek V, Xiang C, Xu H, Rosen V and Xu J: Endothelial cells produce angiocrine factors to regulate bone and cartilage via versatile mechanisms. Theranostics. 10:5957–5965. 2020.PubMed/NCBI View Article : Google Scholar
22	Kusumbe AP, Ramasamy SK and Adams RH: Coupling of angiogenesis and osteogenesis by a specific vessel subtype in bone. Nature. 507:323–328. 2014.PubMed/NCBI View Article : Google Scholar
23	Zhu S, Yao F, Qiu H, Zhang G, Xu H and Xu J: Coupling factors and exosomal packaging microRNAs involved in the regulation of bone remodelling. Biol Rev Camb Philos Soc. 93:469–480. 2018.PubMed/NCBI View Article : Google Scholar
24	Street J, Winter D, Wang JH, Wakai A, McGuinness A and Redmond HP: Is human fracture hematoma inherently angiogenic? Clin Orthop Relat Res. 378:224–237. 2000.PubMed/NCBI View Article : Google Scholar
25	Stuttfeld E and Ballmer-Hofer K: Structure and function of VEGF receptors. IUBMB Life. 61:915–922. 2009.PubMed/NCBI View Article : Google Scholar
26	Carmeliet P and Jain RK: Molecular mechanisms and clinical applications of angiogenesis. Nature. 473:298–307. 2011.PubMed/NCBI View Article : Google Scholar
27	Simons M, Gordon E and Claesson-Welsh L: Mechanisms and regulation of endothelial VEGF receptor signalling. Nat Rev Mol Cell Biol. 17:611–625. 2016.PubMed/NCBI View Article : Google Scholar
28	Nelson WJ and Nusse R: Convergence of Wnt, beta-catenin, and cadherin pathways. Science. 303:1483–1487. 2004.PubMed/NCBI View Article : Google Scholar
29	Blaschuk OW: N-cadherin antagonists as oncology therapeutics. Philos Trans R Soc Lond B Biol Sci. 370(20140039)2015.PubMed/NCBI View Article : Google Scholar
30	Sabatini PJ, Zhang M, Silverman-Gavrila R, Bendeck MP and Langille BL: Homotypic and endothelial cell adhesions via N-cadherin determine polarity and regulate migration of vascular smooth muscle cells. Circ Res. 103:405–412. 2008.PubMed/NCBI View Article : Google Scholar
31	Tomita K, van Bokhoven A, van Leenders GJ, Ruijter ET, Jansen CF, Bussemakers MJ and Schalken JA: Cadherin switching in human prostate cancer progression. Cancer Res. 60:3650–3654. 2000.PubMed/NCBI
32	Heasman SJ and Ridley AJ: Mammalian Rho GTPases: New insights into their functions from in vivo studies. Nat Rev Mol Cell Biol. 9:690–701. 2008.PubMed/NCBI View Article : Google Scholar
33	Dong M, Yan BP, Liao JK, Lam YY, Yip GW and Yu CM: Rho-kinase inhibition: A novel therapeutic target for the treatment of cardiovascular diseases. Drug Discov Today. 15:622–629. 2010.PubMed/NCBI View Article : Google Scholar
34	Lock FE and Hotchin NA: Distinct roles for ROCK1 and ROCK2 in the regulation of keratinocyte differentiation. PLoS One. 4(e8190)2009.PubMed/NCBI View Article : Google Scholar
35	Wu YJ, Tang Y, Li ZF, Li Z, Zhao Y, Wu ZJ and Su Q: Expression and significance of Rac1, Pak1 and Rock1 in gastric carcinoma. Asia Pac J Clin Oncol. 10:e33–e39. 2014.PubMed/NCBI View Article : Google Scholar
36	Lou Z, Billadeau DD, Savoy DN, Schoon RA and Leibson PJ: A role for a RhoA/ROCK/LIM-kinase pathway in the regulation of cytotoxic lymphocytes. J Immunol. 167:5749–5757. 2001.PubMed/NCBI View Article : Google Scholar
37	Noma K, Rikitake Y, Oyama N, Yan G, Alcaide P, Liu PY, Wang H, Ahl D, Sawada N, Okamoto R, et al: ROCK1 mediates leukocyte recruitment and neointima formation following vascular injury. J Clin Invest. 118:1632–1644. 2008.PubMed/NCBI View Article : Google Scholar
38	Lock FE, Ryan KR, Poulter NS, Parsons M and Hotchin NA: Differential regulation of adhesion complex turnover by ROCK1 and ROCK2. PLoS One. 7(e31423)2012.PubMed/NCBI View Article : Google Scholar
39	Dang CV, O'Donnell KA, Zeller KI, Nguyen T, Osthus RC and Li F: The c-Myc target gene network. Semin Cancer Biol. 16:253–264. 2006.PubMed/NCBI View Article : Google Scholar
40	Baudino TA, McKay C, Pendeville-Samain H, Nilsson JA, Maclean KH, White EL, Davis AC, Ihle JN and Cleveland JL: c-Myc is essential for vasculogenesis and angiogenesis during development and tumor progression. Genes Dev. 16:2530–2543. 2002.PubMed/NCBI View Article : Google Scholar
41	Song G, Ouyang G and Bao S: The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med. 9:59–71. 2005.PubMed/NCBI View Article : Google Scholar
42	Peiris TH, Ramirez D, Barghouth PG and Oviedo NJ: The Akt signaling pathway is required for tissue maintenance and regeneration in planarians. BMC Dev Biol. 16(7)2016.PubMed/NCBI View Article : Google Scholar
43	Abeyrathna P and Su Y: The critical role of Akt in cardiovascular function. Vascul Pharmacol. 74:38–48. 2015.PubMed/NCBI View Article : Google Scholar
44	Radisavljevic Z: AKT as locus of cancer phenotype. J Cell Biochem. 116:1–5. 2015.PubMed/NCBI View Article : Google Scholar
45	Zhai H, Pan T, Yang H, Wang H and Wang Y: Cadmium induces A549 cell migration and invasion by activating ERK. Exp Ther Med. 18:1793–1799. 2019.PubMed/NCBI View Article : Google Scholar
46	Gough NR: Focus issue: Recruiting players for a game of ERK. Sci Signal. 4(eg9)2011.PubMed/NCBI View Article : Google Scholar
47	Liu P and Zhong TP: MAPK/ERK signalling is required for zebrafish cardiac regeneration. Biotechnol Lett. 39:1069–1077. 2017.PubMed/NCBI View Article : Google Scholar
48	Lin F, Chengyao X, Qingchang L, Qianze D, Enhua W and Yan W: CRKL promotes lung cancer cell invasion through ERK-MMP9 pathway. Mol Carcinog 54 Suppl. 1:E35–E44. 2015.PubMed/NCBI View Article : Google Scholar
49	Gillard JA, Reed MW, Buttle D, Cross SS and Brown NJ: Matrix metalloproteinase activity and immunohistochemical profile of matrix metalloproteinase-2 and -9 and tissue inhibitor of metalloproteinase-1 during human dermal wound healing. Wound Repair Regen. 12:295–304. 2004.PubMed/NCBI View Article : Google Scholar
50	Raeeszadeh-Sarmazdeh M, Do LD and Hritz BG: Metalloproteinases and their inhibitors: Potential for the development of new therapeutics. Cells. 9(1313)2020.PubMed/NCBI View Article : Google Scholar
51	Shi YN, Zhu N, Liu C, Wu HT, Gui Y, Liao DF and Qin L: Wnt5a and its signaling pathway in angiogenesis. Clin Chim Acta. 471:263–269. 2017.PubMed/NCBI View Article : Google Scholar
52	Yao L, Sun B, Zhao X, Zhao X, Gu Q, Dong X, Zheng Y, Sun J, Cheng R, Qi H and An J: Overexpression of Wnt5a promotes angiogenesis in NSCLC. Biomed Res Int. 2014(832562)2014.PubMed/NCBI View Article : Google Scholar
53	Silvério KG, Davidson KC, James RG, Adams AM, Foster BL, Nociti FH Jr, Somerman MJ and Moon RT: Wnt/β-catenin pathway regulates bone morphogenetic protein (BMP2)-mediated differentiation of dental follicle cells. J Periodontal Res. 47:309–319. 2012.PubMed/NCBI View Article : Google Scholar